Announcing the receipt of CLIA Waiver for DPP HIV-Syphilis. Contact your local Chembio Representative for more information
Biosynex Completes Acquisition of Chembio Diagnostics, Inc.
Chembio Diagnostics, Inc. becomes the first North American structure controlled by Biosynex in North America STRASBOURG,…
Chembio Announces the Receipt of CLIA Waiver for its DPP HIV-Syphilis System
MEDFORD, N.Y., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on…
Chembio Diagnostics Awarded $3.2 Million Contract from the CDC for Development and Clinical Validation of Dual-Path Platform Syphilis Screen & Confirm Assay
HAUPPAUGE, N.Y., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused…
About Us
We enable longer and healthier living through detection and monitoring of infectious diseases at the point of care.
Our mission is to be a leader in the development, manufacturing and commercialization of diagnostic solutions. We are dedicated to delivering exceptional point-of-care products that are easy to use, fast and accurate.
Our Core Values: “RAPID”
Investor Relations
Chembio is a leading point of care diagnostics company focused on detecting and diagnosing infectious diseases.
Our patented DPP® technology platform uses a small drop of blood from the fingertip and provides high-quality, cost-effective results in 15-20 minutes. Our products are sold globally, directly and through distributors, to hospitals, clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers.
